Compare SMID & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | RPID |
|---|---|---|
| Founded | 1960 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 204.3M |
| IPO Year | 1996 | 2021 |
| Metric | SMID | RPID |
|---|---|---|
| Price | $34.25 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 4.0K | ★ 133.0K |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 866.67 | 11.48 |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $78,508,000.00 | $28,051,000.00 |
| Revenue This Year | N/A | $19.91 |
| Revenue Next Year | N/A | $21.68 |
| P/E Ratio | $18.04 | ★ N/A |
| Revenue Growth | ★ 31.77 | 24.57 |
| 52 Week Low | $25.16 | $1.86 |
| 52 Week High | $43.62 | $4.94 |
| Indicator | SMID | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 49.93 |
| Support Level | $33.59 | $2.92 |
| Resistance Level | $37.90 | $4.49 |
| Average True Range (ATR) | 1.47 | 0.26 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 27.63 | 41.72 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.